OR WAIT null SECS
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
WuXi STA is opening a new large-scale oligonucleotide and peptide manufacturing facility.
WuXi STA, a subsidiary of WuXi AppTec, is opening a new large-scale continuous manufacturing plant at its Changzhou campus. The facility will focus on increasing capacity and capability to meet the fast-growing customer needs for oligonucleotide and peptide therapeutics development and manufacturing worldwide.
The new oligonucleotide plant will be 30,570 sq. ft. and will include four large-scale oligonucleotide production lines and more than 20 small-to-mid-scale production lines that increase the overall manufacturing capacity of a single synthesis run from 1.9 mol to 6.0 mol.
The peptide plant will be 22,260 sq. ft. and feature three new production lines with reactors that can accommodate up to 1000 L, increasing WuXi STA’s overall Solid Phase Peptide Synthesis (SPPS) total reactor volume to 6490 L.
“We are pleased to support our global partners in their efforts to develop new modality therapies for patients in need,” said Dr. Minzhang Chen, Co-CEO of WuXi AppTec and CEO of WuXi STA, in a press release. “WuXi STA is committed to enabling partners by enhancing our new modality CRDMO platform’s capacity and capability to expedite the development and commercialization of more innovative therapies to benefit patients worldwide.”
Source: WuXi AppTec